Related Experiment Videos
Aberrant immunophenotypes of mantle cell lymphomas.
Ch Wohlschlaeger1, K Lange, H Merz
1Institute of Pathology, University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany.
Leukemia & Lymphoma
|April 12, 2003
Summary
Mantle cell lymphomas (MCL) exhibit characteristic features, but aberrant immunophenotypes occur. Recognizing these variations, like CD5-negativity or CD23-positivity, is crucial for accurate differential diagnosis of B-cell lymphomas.
Area of Science:
- Hematology
- Oncology
- Immunopathology
Background:
- Mantle cell lymphoma (MCL) is a B-cell neoplasm defined by specific cytomorphology, immunophenotype (CD5+, CD23-), and the t(11;14) translocation.
- Immunohistochemistry aids in differentiating MCL from other B-cell lymphomas, such as B-cell chronic lymphocytic leukemia (B-CLL).
Purpose of the Study:
- To analyze the morphological, immunophenotypical, and genetic features of 50 MCL cases.
- To identify and characterize MCL cases with aberrant immunophenotypes.
Main Methods:
- Morphological assessment of lymphoma cells.
- Immunohistochemical analysis for CD5, CD23, and cyclin D1 expression.
- Karyotyping to detect the t(11;14) translocation.
Main Results:
- All 50 MCL cases showed cyclin D1 expression.
- Five cases presented aberrant immunophenotypes: three lacked CD5 expression, and two showed CD23 positivity.
- Despite aberrant markers, cyclin D1 was consistently expressed in these five cases.
Conclusions:
- A subset of MCL cases exhibits aberrant immunophenotypes, challenging traditional diagnostic criteria.
- These aberrant immunophenotypes, particularly CD5-negativity and CD23-positivity, must be considered during the differential diagnosis of B-cell lymphomas.
- Cyclin D1 expression remains a reliable marker for MCL, even in cases with unusual immunophenotypic profiles.